Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY
We describe differences in adverse clinical outcomes associated with sequencing of biologics in patients with CD or UC and demonstrate favorable results in patients who received vedolizumab as a first-line biologic. These results provide potential guidance to clinicians choosing sequences of biologic treatments in patients with IBD.
Authors
- Benjamin Chastek (ORCID: https://orcid.org/0000-0002-9759-6001)
- Sabyasachi Ghosh (ORCID: https://orcid.org/0000-0003-1212-824X)
- Tao Fan (ORCID: https://orcid.org/0000-0001-9318-9452)
- Tim Bancroft (ORCID: https://orcid.org/0000-0002-4998-582X)
- David T. Rubin (ORCID: https://orcid.org/0000-0001-5647-1723)
- Noa Krugliak Cleveland (ORCID: https://orcid.org/0000-0003-1707-8560)
- Kandavadivu Umashankar (ORCID: https://orcid.org/0000-0003-1138-8533)
- Ninfa Candela (ORCID: https://orcid.org/0000-0003-3469-6088)
Institutions
- University of Chicago (US)
- Optum (United States) (US)
- Takeda (United States) (US)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1186/s12876-024-03378-6
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- Takeda Pharmaceuticals U.S.A.